文献速递心境障碍

经颅直流电刺激增强认知行为疗法治疗抑郁症的随机临床试验

Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

在德国6所大学医院开展的双盲安慰剂对照随机临床试验PsychotherapyPlus纳入148例成人重性抑郁障碍患者,比较单纯认知行为疗法(CBT)、CBT联合经颅直流电刺激(tDCS)与CBT联合假tDCS的疗效。主要结局MADRS评分变化显示各组随时间均改善,但组间及组×时间交互效应均无统计学显著差异,未见tDCS增强CBT的优越疗效;同步团体CBT与tDCS安全可行。

要点

  • 三组MADRS评分随时间平均降低6.5分(95%CI 3.82-9.14),Cohen d=-0.90(95%CI -1.43至-0.50)。
  • 组间效应及组×时间交互效应均无统计学显著差异,tDCS增强CBT未见优越疗效。
  • 全程无严重不良事件,组1与组2刺激期间及之后自我报告的不良反应无显著差异。

核心结论

  • 基于MADRS评分变化,本试验未显示tDCS增强CBT相较于两种CBT对照条件具有优越疗效。
  • 研究确认同步团体CBT与tDCS安全可行,但需要进一步研究神经调控机制以补充CBT及其他行为干预。

研究设计与样本

  • 双盲、安慰剂对照随机临床试验PsychotherapyPlus在德国6所大学医院开展,入组时间为2016年6月2日至2020年3月10日,随访于2020年8月27日完成。
  • 共148例20至65岁单次或复发性抑郁发作成人患者接受随机分组:单纯CBT组(组0)53例、CBT联合tDCS组(组1)48例、CBT联合假tDCS组(组2)47例。
  • 干预为为期6周的团体干预,包含12次CBT课程;tDCS同步施加,活性tDCS强度为2 mA持续30分钟(阳极置于F3、阴极置于F4)。
  • 主要结局为意向治疗样本中MADRS评分从基线至治疗后变化;MADRS 0至6分表示无抑郁,7至19分轻度抑郁,20至34分中度抑郁,34分及以上重度抑郁。

主要发现

  • 共148例患者(89例女性、59例男性;平均[SD]年龄41.1[13.7]岁;基线MADRS评分23.0[6.4])接受随机分组,其中126例患者(平均[SD]年龄41.5[14.0]岁;基线MADRS评分23.0[6.3])完成研究。
  • 每个干预组的MADRS评分平均降低6.5分(95%CI 3.82-9.14),Cohen d值为-0.90(95%CI -1.43至-0.50),提示随时间变化具有显著效应。
  • 组间效应及组×时间交互效应均无统计学显著差异,提示估计的附加效应未达统计学显著。
  • 整个试验期间无严重不良事件,组1与组2在刺激期间及之后自我报告的不良反应无显著差异。

关键数值与推荐

  • 主要结局为意向治疗样本MADRS评分从基线至治疗后的变化。
  • MADRS评分0至6分表示无抑郁,7至19分表示轻度抑郁,20至34分表示中度抑郁,34分及以上表示重度抑郁。
  • 活性tDCS参数为2 mA、30分钟,阳极置于F3、阴极置于F4,与团体CBT同步施加。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文结论指出,需要进一步研究神经调控机制以补充CBT及其他行为干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Major depressive disorder (MDD) affects approximately 10% of the population globally. Approximately 20% to 30% of patients with MDD do not sufficiently respond to standard treatment. Therefore, there is a need to develop more effective treatment strategies. OBJECTIVE: To investigate whether the efficacy of cognitive behavioral therapy (CBT) for the treatment of MDD can be enhanced by concurrent transcranial direct current stimulation (tDCS). DESIGN, SETTING, AND PARTICIPANTS: The double-blind, placebo-controlled randomized clinical trial PsychotherapyPlus was conducted at 6 university hospitals across Germany. Enrollment took place between June 2, 2016, and March 10, 2020; follow-up was completed August 27, 2020. Adults aged 20 to 65 years with a single or recurrent depressive episode were eligible. They were either not receiving medication or were receiving a stable regimen of antidepressant medication (selective serotonin reuptake inhibitor and/or mirtazapine). A total of 148 women and men underwent randomization: 53 individuals were assigned to CBT alone (group 0), 48 to CBT plus tDCS (group 1), and 47 to CBT plus sham-tDCS (group 2). INTERVENTIONS: Participants attended a 6-week group intervention comprising 12 sessions of CBT. If assigned, tDCS was applied simultaneously. Active tDCS included stimulation with an intensity of 2 mA for 30 minutes (anode over F3, cathode over F4). MAIN OUTCOMES AND MEASURES: The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to posttreatment in the intention-to-treat sample. Scores of 0 to 6 indicate no depression; 7 to 19, mild depression; 20 to 34, moderate depression; and 34 and higher, severe depression. RESULTS: A total of 148 patients (89 women, 59 men; mean [SD] age, 41.1 [13.7] years; MADRS score at baseline, 23.0 [6.4]) were randomized. Of these, 126 patients (mean [SD] age, 41.5 [14.0] years; MADRS score at baseline, 23.0 [6.3]) completed the study. In each of the intervention groups, intervention was able to reduce MADRS scores by a mean of 6.5 points (95% CI, 3.82-9.14 points). The Cohen d value was -0.90 (95% CI, -1.43 to -0.50), indicating a significant effect over time. However, there was no significant effect of group and no significant interaction of group × time, indicating the estimated additive effects were not statistically significant. There were no severe adverse events throughout the whole trial, and there were no significant differences of self-reported adverse effects during and after stimulation between groups 1 and 2. CONCLUSIONS AND RELEVANCE: Based on MADRS score changes, this trial did not indicate superior efficacy of tDCS-enhanced CBT compared with 2 CBT control conditions. The study confirmed that concurrent group CBT and tDCS is safe and feasible. However, additional research on mechanisms of neuromodulation to complement CBT and other behavioral interventions is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02633449.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Aust S, Brakemeier EL, Spies J, et al. Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 35442431. doi:10.1001/jamapsychiatry.2022.0696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。